欢迎来到《四川大学学报(医学版)》

二代测序技术检测胃癌患者基因突变及其临床病理特征分析

Next-Generation Sequencing-Based Detection of Gene Mutations and Its Association With Clinicopathological Features in Gastric Cancer

  • 摘要:
    目的  分析中国胃癌患者的基因突变特征,探讨其与临床病理特征及预后的相关性。
    方法  纳入55例胃癌患者,采用二代测序(next-generation sequencing, NGS)检测肿瘤相关基因突变、微卫星不稳定性(microsatellite instability, MSI)和肿瘤突变负荷(tumor mutational burden, TMB)。分析高频突变基因与临床病理特征及无进展生存期(progression-free survival, PFS)的关系,并利用TCGA-STAD队列(n=436)验证关键发现及分析种族异质性。
    结果 85.45%(47/55)的患者检出突变,高频体系突变基因包括TP53(29.09%)、ARID1A(16.36%)、CDH1(14.55%)、LRP1B(14.55%)和PIK3CA(12.73%)。TP53突变与T4分期(P=0.028)和弥漫型胃癌(P=0.008)相关;CDH1突变与印戒细胞癌(P=0.012)和低分化肿瘤相关(P=0.006)。20%(11/55)的患者携带致病性胚系突变。单变量生存分析显示,CDH1突变是PFS的独立不良预后因素〔风险比(hazard ratio, HR)=3.110,95%置信区间(confidence interval, CI):3.370~20.000〕。TCGA队列验证证实,CDH1突变的不良预后效应仅存在于亚洲人群(HR=5.00,95%CI:2.01~12.43),表明存在种族的异质性。
    结论 中国胃癌患者具有独特的基因突变谱,关键基因突变与肿瘤侵袭性密切相关。本研究通过多队列验证提示CDH1等基因的预后价值可能存在种族差异,强调在中国人群中进行精准分子分型的必要性。

     

    Abstract:
    Objective To analyze the gene mutation profile of Chinese patients with gastric cancer and to explore its correlations with clinicopathological characteristics and prognosis.
    Methods Fifty-five patients with gastric cancer were enrolled. Next-generation sequencing was performed to detect mutations in cancer-related genes, microsatellite instability, and tumor mutational burden. The associations of high-frequency mutated genes with clinicopathological features and progression-free survival (PFS) were analyzed. Key findings were validated and ethnic heterogeneity was assessed using The Cancer Genome Atlas stomach adenocarcinoma cohort (n = 436).
    Results Somatic mutations were identified in 85.45% (47/55) of patients. The most frequently mutated genes were TP53 (29.09%), ARID1A (16.36%), CDH1 (14.55%), LRP1B (14.55%), and PIK3CA (12.73%). TP53 mutations were associated with T4 stage (P = 0.028) and diffuse-type gastric cancer (P = 0.008). CDH1 mutations were enriched in signet-ring cell carcinoma (P = 0.012) and poorly differentiated tumors (P = 0.006). Pathogenic germline mutations were identified in 20% (11/55) of patients. Univariate survival analysis revealed that CDH1 mutation was an independent poor prognostic factor for PFS (hazard ratio = 3.110, 95% confidence interval: 3.370-20.000). Validation in The Cancer Genome Atlas cohort confirmed that the poor prognostic effect of CDH1 mutation was present only in the Asian subgroup (hazard ratio = 5.00, 95% confidence interval: 2.01-12.43), demonstrating significant ethnic heterogeneity.
    Conclusion Chinese patients with gastric cancer exhibit a distinct gene mutation profile, and key gene mutations are closely associated with tumor aggressiveness. This multi-cohort validation study indicates ethnic differences in the prognostic value of genes such as CDH1, highlighting the importance of precision molecular classification in the Chinese population.

     

/

返回文章
返回